Blue March: Pierre Fabre supports colorectal cancer awareness month
Puma regains China rights to Nerlynx and amends deal with Fabre
Pierre Fabre étend ses droits sur le Nerlynx de Puma Biotechnology
Pierre Fabre étend sa collaboration avec Puma Biotechnology
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire
Fight against cancer : our therapeutic responses | Pierre Fabre
Pierre Fabre amends license agreement with Puma Biotechnology - European Biotechnology
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology | Evaluate
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Partners of the Pierre Fabre Group: from health to beauty
Puma regains China rights to Nerlynx and amends deal with Fabre
Accord entre Pierre Fabre et Puma Biotechnology
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Pierre Fabre and ValenzaBio collaborate on anti-IGF-1R antibody for TE
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
Puma licences breast cancer therapy Nerlynx to Pierre Fabre in Europe
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies | Pierre Fabre Pharma Norden AB
Puma Biotech Expands Pierre Fabre License to Add Countries
Puma Bio: A Contrarian Investment That Requires Patience (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | Business Wire
THE FACES OF BREAST CANCER
